Biochemical markers: Summary

References

• Strong MJ. The evidence for ALS as a multisystems disorder of limited phenotypic expression. Can J Neurol Sci 2001; 28: 283–298.
   PubMed Web of Science ®Google Scholar
• World Federation of Neurology Research Group on Neuro- muscular Disease. El Escorial World Federation of Neurol- ogy criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 1994; 124(Suppl): 96–107.
   Google Scholar
• Ross MA, Miller RG, Berchert L et al. Toward earlier diagno- sis of amyotrophic lateral sclerosis. Neurology 1998; 50: 768–772.
   Google Scholar
• Strong MJ, Grace GM, Orange JB, Leeper HA, Menon R, Aere A prospective study of cognitive impairment in ALS. Neu- rology 1999; 53: 1665–1670.
   Google Scholar
• Wilson CM, Grace GM, Munoz DG, He BP, Strong MJ. Cog- nitive impairment in sporadic ALS. A pathological contin- uum underlying a multisystem disorder. Neurology 2001; 57: 651–657.
   Google Scholar
• Anderson PM, Morita M, Brown RH Jr. Genetics of amy- otrophic lateral sclerosis: an overview. In: Brown RH Jr, Meininger V, Swash M, eds. Amyotrophic Lateral Sclerosis. London: Martin Dunitz, 2000: 223–250.
   Google Scholar
• Norris FH, Burns W, Kwei SÜ, Mukai E, Norris H. Spinal fluid cells and protein in amyotrophic lateral sclerosis. Arch Neurol 2001; 50: 489–491.
   Google Scholar
• Younger DS, Rowland LP, Latov N et al. Motor neuron disease and amyotrophic lateral sclerosis: relation of high CSF protein content to paraproteinemia and clinical syn- dromes. Neurology 1990; 40: 595–599.
   Google Scholar
• Stevens A, Weller M, Wiethölter H. A characteristic ganglio- side antibody pattern in the CSF of patients with amy- otrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 1993; 56: 361–364.
   PubMed Web of Science ®Google Scholar
• Camu W, Billiard M, Baldy-Moulinier M. Fasting plasma and CSF amino acid levels in amyotrophic lateral sclerosis: a subtype analysis. Acta Neurol Scand 1993; 88: 51–55.
   PubMed Web of Science ®Google Scholar
• Shaw PJ, Williams R. Serum and cerebrospinal fluid bio- chemical markers of ALS. ALS 2000; 1(Suppl): S61–S67.
   Google Scholar
• Tumani H, Shen G, Peter JB, Brück W. Glutamine synthetase in cerebrospinal fluid, serum, and brain. Arch Neurol 1999; 56: 1241–1246.
   PubMedGoogle Scholar
• Fujita K, Honda M, Hayashi R et al. Transglutaminase activity in serum and cerebrospinal fluid in sporadic amyotrophic lateral sclerosis: a possible use as an indicator of extent of the motor neuron loss. J Neurol Sci 1998; 158: 53–57.
   Google Scholar
• Niebroj-Dobosz I, Janik P. Amino acids acting as transmit- ters in amyotrophic lateral sclerosis (ALS). Acta Neurol Scand 1999; 100: 6–11.
   PubMed Web of Science ®Google Scholar
• Iwasaki Y, Ikeda K, Kinoshita M. Plasma amino acid levels in patients with amyotrophic lateral sclerosis. J Neurol Sci 1992; 107: 219–222.
   PubMedGoogle Scholar
• Heafield MT, Fearn S, Steventon GB, Waring RH, Williams AC, Sturman GA. Plasma cysteine and sulfate levels in patients with motor-neurone, Parkinson’s and Alzheimer’s disease. Neurosci Lett 1990; 110: 216–220.
   PubMed Web of Science ®Google Scholar
• Anagnostouli M, Livaniou E, Nyalala JO et al. Cerebrospinal fluid levels of biotin in various neurological disorders. Acta Neurol Scand 1999; 99: 387–392.
   Google Scholar
• Bogdanov MB, Brown RH Jr, Matson W et al. Increased oxidative damage to DNA in ALS patients. Free Rad Biol Med 2000; 29: 652–658.
   PubMed Web of Science ®Google Scholar
• Beal FM, Ferrante RJ, Browne SE, Matthews RT, Kowall NW, Brown RH Jr. Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Ann Neurol 1997; 42: 646–654.
   Web of Science ®Google Scholar
• Tohgi H, Abe T, Yamazaki K, Murata T, Ishizaki E, Isobe C. Increase in oxidized NO products and reduction in oxidized glutathione in cerebrospinal fluid from patients with spor- adic form of amyotrophic lateral sclerosis. Neurosci Lett 1999; 260: 204–206.
   PubMed Web of Science ®Google Scholar
• Tohgi H, Abe T, Yamazaki K, Murata T, Ishizaki E, Isobe C. Remarkable increase in cerebrospinal fluid 3-nitrotyrosine in patients with sporadic amyotrophic lateral sclerosis. Ann Neurol 1999; 46: 129–131.
   PubMed Web of Science ®Google Scholar
• Smith GR, Henry YK, Mattson MP, Appel SH. Presence of 4- hydroxynonenal in cerebrospinal fluid of patients with spor- adic amyotrophic lateral sclerosis. Ann Neurol 1998; 44: 696–699.
   PubMed Web of Science ®Google Scholar
• Krieger C, Perry TL, Ziltener HJ. Amyotrophic lateral scler- osis: interleukin-6 levels in cerebrospinal fluid. Can J Neurol Sci 1992; 19: 357–359.
   PubMed Web of Science ®Google Scholar
• Sekizawa T, Openshaw H, Ohbo K, Sugamura K, Itoyama Y, Niland JC. Cerebrospinal fluid interleukin 6 in amyotrophic lateral sclerosis: immunological parameter and comparison with inflammatory and non-inflammatory central nervous system diseases. J Neurol Sci 1998; 154: 194–199.
   PubMed Web of Science ®Google Scholar
• Hzecka J, Stelmasiak Z, Dobosz B. Interleukin-1b converting enzyme/caspase-1 (ICE/caspase-1) and soluble APO- 1/Fas/CD 95 receptor in amyotrophic lateral sclerosis patients. Acta Neurol Scand 2001; 103: 255–258.
   PubMedGoogle Scholar
• Rosengren LE, Karlsson J-E, Karlsson J-O, Persson LI, Wikkels Patients with amyotrophic lateral sclerosis and other neu- rodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem 1996; 67: 2013–2018.
   PubMed Web of Science ®Google Scholar
• Molina JA, de Bustos F, Jiménez-Jiménez FJ et al. Serum levels of beta-carotene, alpha-carotene, and vitamin A in patients with amyotrophic lateral sclerosis. Acta Neurol Scand 1999; 99: 315–317.
   Google Scholar
• Iwasaki Y, Ikeda K, Kinoshita M. Vitamin A and E levels are normal in amyotrophic lateral sclerosis. J Neurol Sci 1995; 132: 193–194.
   PubMed Web of Science ®Google Scholar
• Oteiza PI, Uchitel OD, Carrasquedo F, Dubrovski AL, Roma JC, Fraga CG. Evaluation of antioxidants, protein, and lipid oxidation products in blood from sporadic amyotrophic lateral sclerosis patients. Neurochem Res 1997; 22: 535–539.
   PubMed Web of Science ®Google Scholar
• Gluck MR, Thomas RG, Sivak MA. Unaltered cytochrome oxidase, glutamate dehydrogenase and glutaminase activities in platelets from patients with sporadic amyotrophic lateral sclerosis. A study of potential pathogenetic mechanisms in neurodegenerative disease. J Neural Trans 2000; 107: 1447.
   Google Scholar
• Kawamata T, Akiyama H, Yamada T, McGeer PL. Immuno- logical reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am J Pathol 1992; 140: 691–707.
   PubMed Web of Science ®Google Scholar
• Kamo H, Haebara H, Akiguchi I, Kameyama M, Kimura H, McGeer PL. A distinctive distribution of reactive astroglia in the precentral cortex in amyotrophic lateral sclerosis. Acta Neuropathol 1987; 74: 33–38.
   PubMed Web of Science ®Google Scholar
• Almer G, Guégan C, Teismann P et al. Increased expression of the pro-inflammatory enzyme cyclooxygenase-2 in amy- otrophic lateral sclerosis. Ann Neurol 2001; 49: 176–185.
   Google Scholar
• Yasojima K, Tourellotte WW, McGeer EG, McGeer PL. Marked increase in cyclooxygenase-2 in ALS spinal cord. Neurology 2001; 57: 952–956.
   PubMed Web of Science ®Google Scholar
• Ono S, Hu J, Shimizu N, Imai T, Nakagawa H. Increased interleukin-6 of skin and serum in amyotrophic lateral scler- osis. J Neurol Sci 2001; 187: 27–34.
   PubMed Web of Science ®Google Scholar
• He BP, Strong MJ. Motor neuronal death in amyotrophic lateral sclerosis (ALS) is not apoptotic. A comparative analy- sis of ALS and chronic aluminum neurotoxicity in New Zealand white rabbits. J Neuropathol Appl Neurobiol 2000; 26: 1–13.
   PubMedGoogle Scholar
• Martin LJ. Neuronal death in amyotrophic lateral sclerosis is apoptosis: possible contribution of a programmed cell death mechanism. J Neuropathol Exp Neurol 1999; 58: 459–471.
   PubMed Web of Science ®Google Scholar
• Martin LJ. p53 is abnormally elevated and active in the CNS of patients with amyotrophic lateral sclerosis. Neurobiol Disease 2000; 7: 613–622.
   PubMed Web of Science ®Google Scholar
• Niebroj-Dobosz I, Jamrozik Z, Janik P, Hausmanowa- Petrusewicz I, Kwiencinski H. Anti-neuronal antibodies in serum and cerebrospinal fluid of amyotrophic lateral scler- osis (ALS) patients. Acta Neurol Scand 1999; 100: 238–243.
   PubMed Web of Science ®Google Scholar
• Pestronk A, Adams RN, Clawson L et al. Serum antibodies to GM1 ganglioside in amyotrophic lateral sclerosis. Neurology 1988; 38: 1457–1461.
   Google Scholar
• Sanders KA, Rowland LP, Murphy PL et al. Motor neuron disease and amyotrophic lateral sclerosis: GM1 antibodies and paraproteinemia. Neurology 1993; 43: 418–420.
   Google Scholar
• Lamb NL, Patten BM. Clinical correlations of anti-GM1 anti- bodies in amyotrophic lateral sclerosis and neuropathies. Muscle Nerve 1991; 14: 1021–1027.
   PubMed Web of Science ®Google Scholar
• Fullmer HM, Siedler HD, Krooth RS, Kurland LT. A cuta- neous disorder of connective tissue in amyotrophic lateral sclerosis. A histochemical study. Neurology 1960; 10: 717–724.
   PubMedGoogle Scholar
• Kolde G, Bachus R, Ludolph AC. Skin involvement in amy- otrophic lateral sclerosis. Lancet 1996; 347: 1227.
   Google Scholar
• Ono S, Matsuno S, Shimizu N, Shoji S, Tamaoka A. Amyoid b protein in skin of patients with amyotrophic lateral scler- osis. Lancet 1998; 351: 956–957.
   PubMedGoogle Scholar
• Ono S, Hu J, Imai T, Shimizu N, Tsumura M, Nakagawa H. Increased expression of insulin-like growth factor I in skin in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2000; 69: 199–203.
   PubMed Web of Science ®Google Scholar
• Ono S, Imai T, Shimizu N, Nagao K. Increased expression of Laminin 1 in the skin of amyotrophic lateral sclerosis. Eur Neurol 2000; 43: 215–220.
   PubMed Web of Science ®Google Scholar
• Ono S, Imai T, Takahashi K, Jinnai K, Shimizu N, Nagao K. Increased type III procollagen in serum and skin of patients with amyotrophic lateral sclerosis. Acta Neurol Scand 1999; 100: 377–384.
   PubMedGoogle Scholar
• Ono S, Imai T, Matsubara S et al. Decreased urinary concen- trations of type IV collagen in amyotrophic lateral sclerosis. Acta Neurol Scand 1999; 100: 111–116.
   Google Scholar
• Ono S, Shimizu N, Imai T, Mihori A, Nagao K. Increased cys- tatin C immunoreactivity in the skin in amyotrophic lateral sclerosis. Acta Neurol Scand 2000; 102: 47–52.
   PubMed Web of Science ®Google Scholar
• Jansen GA, Wanders RJA, Jöbsis GJ, Bolhuis PA, de Jong JMBV. Evidence against increased oxidative stress in fibrob- lasts from patients with non-superoxide-dismutase-1 mutant familial amyotrophic lateral sclerosis. J Neurol Sci 1996; 139: 91–94.
   PubMedGoogle Scholar
• Aguirre T, van den Bosch L, Goetschalckx K et al. Increased sensitivity of fibroblasts from amyotrophic lateral sclerosis patients to oxidative stress. Ann Neurol 1998; 43: 452–457.
   Google Scholar